
Japan approves Sanofi's Sarclisa subcutaneous formulation for multiple myeloma treatment
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
